Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein multitype 1 (ZFPM1), commonly referred to as Friend of GATA protein 1 (FOG-1), is a multi-zinc finger transcription coregulator that is indispensable for normal hematopoiesis [1, 2]. It acts as a primary cofactor for GATA family transcription factors, most notably GATA-1, by mediating the recruitment of the Nucleosome Remodeling and Deacetylase (NuRD) complex to target genes [3, 9]. This interaction is essential for the 'GATA switch' and the subsequent differentiation of erythroid and megakaryocytic cells [31, 32]. Genetic mutations that abrogate the GATA-1/FOG-1 interaction are clinically linked to severe conditions such as X-linked thrombocytopenia and dyserythropoietic anemia [13, 16]. Additionally, FOG-1 has been implicated in cardiac development and the suppression of Th2-mediated immune responses, suggesting its potential as a therapeutic target for allergic diseases [6, 21]. Although there are currently no approved pharmacological agents that directly target FOG-1, research has identified compounds like wogonin that can enhance its binding to GATA-1, and triptolide has been identified as an upstream regulator of its expression [5, 28]. The protein's central role in lineage commitment and its involvement in hematological malignancies like acute megakaryoblastic leukemia make it a high-priority subject for the development of novel transcription factor-directed therapies [17, 35].
Acts as a cofactor for GATA transcription factors (GATA1, GATA2, GATA3) and recruits the NuRD (Nucleosome Remodeling and Deacetylase) complex to regulate gene expression.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein multitype 1 (ZFPM1) (ZFPM1).